Toggle

Introducing NMDP, formerly known as the National Marrow Donor Program and Be The Match. Our name has changed but our mission has not: We save lives through cell therapy. Learn More

Three drugs, treosulfan, fludarabine and lapine T-lymphocyte immune globulin (rATG), before allogeneic (cells from a donor) blood or marrow transplant (BMT) to treat bone marrow failure (BMF) disorders in children, teens and adults (BMT CTN 1904)

Print

1 - 49

Phase 2

24 Locations

NCT04965597

Clinical Trial Goal


To find out if the combination of treosulfan, fludarabine and rATG before allogeneic BMT is safe and works well to treat BMF disorders in children, teens and adults

You may be able to join this trial if you:


  • Are 1 - 49 years old
  • Have a bone marrow failure disorder that can be treated with allogeneic BMT. Some examples are:
    • Congenital amegakaryocytic thrombocytopenia (CAMT)
    • Congenital sideroblastic anemia (CSA)
    • Diamond Blackfan anemia (DFA) 
    • GATA2 deficiency
    • Paroxysmal nocturnal hemoglobinuria (PNH)
    • SAMD9 disorder
    • SAMD9L disorder
    • Shwachman-Diamond syndrome (SDS)
    • Other bone marrow failure disorder, even if the cause is unknown
  • Do not have idiopathic aplastic anemia
  • Do not have Fanconi anemia
  • Do not have dyskeratosis congenita (telomere biology disorder (TBD))
  • Do not have congenital neutropenia
  • Do not have myelodysplastic syndrome (MDS)
  • Do not have leukemia 
  • Have not had an allogeneic BMT
  • Agree to have other standard tests done to see if you can be in the clinical trial 

Trial Details


rATG and tacrolimus are standard drugs used to prevent graft-versus-host disease (GVHD).
Fludarabine, methotrexate and treosulfan are chemotherapy (chemo) drugs that block the growth of cancer.

Before transplant, you'll get:
  • Fludarabine – Given as intravenous (IV) infusions 1 time each day for 5 days. Each infusion takes 1 hour
  • rATG – Given as IV infusions 1 time each day for 3 days. Each infusion takes up to 6 hours
  • Tacrolimus – Given as IV infusions starting 2 days before transplant day
  • Treosulfan – Given as IV infusions 1 time each day for 3 days. Each infusion takes 2 hours

On transplant day, the blood-forming cells from your donor are given to you through an IV infusion.

After transplant, you'll get:
  • Methotrexate – Given as IV infusions 4 times
  • Tacrolimus – Given as IV infusions or as a pill that you take by mouth until at least 6 months after transplant

You'll have have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for 1 year. 

The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. 

Contacts


Adam Mendizabal, PhD, amendizabal@emmes.com

Megan Scott, 240-599-5648, bmtctn1904@emmes.com

Locations

Children's Hospital Los AngelesRecruiting

Los Angeles, California
Kimberly Arieli, karieli@chla.usc.edu

Rady Children's Hospital/UCSDRecruiting

San Diego, California
Contacts:

University of California San FranciscoRecruiting

San Francisco, California
Kevin Magruder, kevin.magruder@ucsf.edu

Children's Hospital ColoradoRecruiting

Aurora, Colorado
Courtney Newbold, Courtney.Newbold@childrenscolorado.org

Children's Healthcare of AtlantaRecruiting

Atlanta, Georgia
Judson Russell, judson.russell@choa.org

Johns Hopkins UniversityRecruiting

Baltimore, Maryland
Jennifer Courneya, jcourne2@jhmi.edu

Boston Children's HospitalRecruiting

Boston, Massachusetts
Brandi Bratrude, brandi.bratrude@childrens.harvard.edu

University of Michigan Medical CenterRecruiting

Ann Arbor, Michigan
Connie Varner, convarne@med.umich.edu

University of MinnesotaRecruiting

Minneapolis, Minnesota
Merve Tekmen, tekme002@umn.edu

St. Louis Children's HospitalRecruiting

Saint Louis, Missouri
Lisa Murray, Murraylm@wustl.edu

Cohen Children's Hospital of NYRecruiting

Queens, New York
Amelia Halac, dhalac@northwell.edu

Memorial Sloan Kettering Cancer CenterRecruiting

New York, New York
Kirsten Fuller

Roswell Park Comprehensive Cancer CenterRecruiting

Buffalo, New York
Rachel Carter, Rachel.Carter@Roswellpark.org

Duke University Medical CenterRecruiting

Durham, North Carolina
Erin Arbuckle, erin.arbuckle@duke.edu

Cincinnati Children's HospitalRecruiting

Cincinnati, Ohio
Samantha (Sam) McBride, samantha.mcbride@cchmc.org

Nationwide Children's HospitalRecruiting

Columbus, Ohio
Lori Jewell, lori.jewell@nationwidechildrens.org

Oregon Health & Science UniversityRecruiting

Portland, Oregon
Rebecca Hulme, hulmer@ohsu.edu

Children's Hospital of PhiladelphiaRecruiting

Philadelphia, Pennsylvania
Patricia Hankins, hankinsp@chop.edu

Vanderbilt University Medical CenterRecruiting

Nashville, Tennessee
Delia Darst, delia.h.darst@vumc.org

MD Anderson Cancer CenterRecruiting

Houston, Texas
Marissa Rose, mmrose@mdanderson.org

Texas Children's HospitalRecruiting

Houston, Texas
Emily Jobe, emilia.jobe@bcm.edu

Primary Children's/University of UtahRecruiting

Salt Lake City, Utah
Rebecca Stoffel, rebecca.stoffel@hsc.utah.edu

Fred Hutch/University of Washington Cancer ConsortiumRecruiting

Seattle, Washington
Courtney Vandervlugt, cvanderv@fredhutch.org

Medical College of Wisconsin/Children's Hospital of WisconsinRecruiting

Milwaukee, Wisconsin
Emily Ruskiewicz, eruszkiewicz@mcw.edu

ClinicalTrials.gov record


NCT04965597. First posted on 7/16/21

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator

1-888-814-8610
contact@ctsearchsupport.org